US › Healthcare

Xilio Development Inc (XLO)

US · Healthcare · Biotechnology

$9.09+0.44%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$12.6M
Revenue YoY
+331.7%
Net profit
$-9.5M
Profit YoY
+28.2%
EPS
$-0.58
EPS estimate
$-0.66
Net margin
-75.3%

EPS came in at -0.58 against a street estimate of -0.66 — a beat of 11.7%.

Key statistics

Market cap
$59.5M
Forward P/E
0.0
P/B
0.83
Book value
$7.79
EPS (TTM)
$-2.26
52-week high
$12.74
52-week low
$6.47
50-day MA
$8.71
200-day MA
$8.93
Beta
-0.12

Analyst view

Analysts rate Xilio Development Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Shareholding

Insiders
28.58%
Institutions
51.84%

Largest institutional holders

FundStake
Bain Capital Life Sciences Investors, LLC10.10%
Frazier Life Sciences Management, L.P.6.43%
Sio Capital Management, LLC2.32%
Vanguard Capital Management, LLC1.88%
Caligan Partners LP1.71%
Merck & Co Inc1.61%
Stonepine Capital Management Llc0.98%
Morgan Stanley - Brokerage Accounts0.87%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Xilio Development Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.